New facility to put Scotland at global forefront of regenerative medicine
A world-leading centre for excellence in regenerative medicine and stem cells is to be built in Edinburgh, Ministers confirmed. Funding support of £24 million from the Scottish Executive will allow the £59 million Scottish Centre for Regenerative Medicine (SCRM) to be developed by the University of Edinburgh in close collaboration with Scottish Enterprise. The SCRM, which will be part of the new Centre for Biomedical Research at Edinburgh's Little France, will be unique in Europe and is thought to be equalled only by Kobe in Japan on a global level.
In providing state-of-the-art research facilities, manufacturing capacity and commercialisation facilities, the SCRM will have three main elements:
- High-quality accommodation to support 220 academic researchers,
- A centre for 'scale-up' development and manufacture of cells,
- Multi-occupancy space to house commercial regenerative medicine research organisations and spin-outs
First Minister Jack McConnell said: "The SCRM will provide a focal point for Scotland's well-established strengths in regenerative medicine using stem cell technologies. The creation of this world-class centre will position Scotland as the leading UK and European location for this vital area of medical development, while also acting as a strong magnet to attract the best scientists, clinicians and regenerative medicine companies to our country. The technologies and potential health treatments based on stem cell research have tremendous potential for both health and economic development, with the prospect of delivering significant breakthroughs in the clinical treatment of some of the most degenerative diseases."
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
CV Therapeutics Submits New Drug Application For Regadenoson

IOmx Therapeutics raises EUR 65 million in Series B round - The new funds will be used to advance iOmx´ lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology
